Anadys Halts Trial

Anadys Pharmaceuticals Inc. (ANDS) halted dosing of hepatits C patients in its clinical trial of ANA975 while the company awaits further analysis of toxicology studies. Shares of Anadys plunged $3.18 to $3.51.